Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 5, 1999, Pages 576-582

  Iyer, Lalitha ^a   Hall, Diana ^b   Das, Soma ^b   Mortell, Melissa A ^b   Ramírez, Jacqueline ^b   Kim, Sarang ^b   Di Rienzo, Anna ^b   Ratain, Mark J ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN DEETHYLASE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BILIRUBIN; BILIRUBIN GLUCURONIDE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; MAGNESIUM CHLORIDE; PHOSPHATIDYLCHOLINE; SACCHAROLACTONE; TRITON X 100; URIDINE DIPHOSPHATE GALACTOSE;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME DEFICIENCY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GILBERT DISEASE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; TATA BOX;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; CAMPTOTHECIN; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0032934383     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70078-0     Document Type: Article

References (43)

1. 1. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett and Doull's toxicology: the basic science of poisons. New York: McGraw-Hill; 1996. p. 113-86.
2. 2. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi PLM, Jansen D, et al. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991;10:487-94.
3. 3. Clarke DJ, Burchell B. The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In: Kaufmann FC, editor. Handbook of experimental pharmacology. Berlin, Heidelberg: Springer-Verlag; 1994. p. 3-43.
4. 4. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-69.
5. 5. Iyer L, King CD, Roy SK, Whitington PR, Tephly TR, Coffman B, et al. Genetic predisposition to the metabolism of irinotecan: role of UGT1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
6. 6. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952;10:169-80.
7. 7. Gilbert A, Lereboullet P. Travaux originaux. La Semaine Medicale 1901;21:241-43.
8. 8. Araki E, Ishikawa M, Ligo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993;84:697-702.
9. 9. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991;21:1159-69.
10. 10. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
11. 11. Gupta E, Mick R, Ramirez J, Wang X, Lestingi T, Vokes EE, Ratain MJ. Pharmacokinetics and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
12. 12. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RPJ, Chowdhury JR, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994;269:17960-4.
13. 13. Jansen PLM, Bosma PJ, Chowdhury JR. Molecular biology of bilirubin metabolism. Prog Liver Dis 1995;13:125-30.
14. 14. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CTM, Chowdhury JR, Chowdhury NR, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994;94:2385-91.
15. 15. Bosma PJ, Chowdhury JR, Huang TJ, Lahiri P, Oude Elferink RPJ, Es HHG, et al. Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I. FASEB J 1992;6:2859-63.
16. 16. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RPJ, Jansen PLM, et al. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992;15:941-7.
17. 17. Aono S, Yamada Y, Keino H, Sasaoka Y, Nakagawa T, Onishi S, et al. A new type of defect in the gene of bilirubin uridine 5′-diphosphate-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type I. Pediatr Res 1994;35:629-32.
18. 18. Erps LT, Ritter JK, Hersh JH, Blossom D, Martin NC, Owens IS. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. J Clin Invest 1994;93:564-70.
19. 19. Labrune P, Myara A, Hadchouel M, Ronchi F, Bernard O, Trivin F, et al. Genetic heterogeneity of Crigler-Najjar syndrome type I: a study of 14 cases. Hum Genet 1994;94:693-7.
20. 20. Ciotti M, Obaray R, Martin MG, Owens IS. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. Am J Med Genet 1997;68:173-8.
21. 21. Bosma PJ, Goldhoorn B, Oude Elferink RPJ, Sinaasappel M, Oostra BA, Jansen PLM. A mutation in bilirubin uridine 5′-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-Najjar syndrome type II. Gastroenterology 1993;105:216-20.
22. 22. Moghrabi N, Clarke DJ, Boxer M, Burchell B. Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics 1993;18:171-3.
23. 23. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
24. 24. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996;347:578-81.
25. 25. Iyer L, Roy SK, Ratain MJ. In vitro glucuronidation of SN-38, the active metabolite of irinotecan (CPT-11) in human liver microsomes [abstract]. Proc Am Soc Clin Oncol 1996;15:1589.
26. 26. Matern H, Heinemann H, Matern S. Radioassay of UDP-glucuronosyltransferase activities toward endogenous substrates using labeled UDP-glucuronic acid and an organic solvent extraction procedure. Anal Biochem 1994;219:182-8.
27. 27. Purba HS, Maggs JL, Orme MLE, Back DJ, Park BK. The metabolism of 17-ethinyl-oestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987;23:447-53.
28. 28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the protein-dye binding. Anal Biochem 1976;72:248-54.
29. 29. Evans RR, Relling MV. Automated high-performance liquid chromatograhic assay for the determination of 7-ethoxycoumarin and umbelliferone. J Chromatogr 1992; 578:141-5.
30. 30. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Genet 1974;12:152-6.
31. 31. Monaghan G, Foster B, Jurima-Romet M, Hume R, Burchell B. UGT1*1 genotyping in a Canadian Inuit population. Pharmacogenetics 1997;7:153-6.
32. 32. Aono S, Adachi Y, Uyama E, Yamada Y, Keino H, Nanno T, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995;345: 958-60.
33. 33. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert's syndrome. Lancet 1996;347:557-8.
34. 34. Soeda Y, Yamamoto K, Adachi Y, Hori T, Aono S, Koiwai O, et al. Predicted homozygous mis-sense mutation in Gilbert's syndrome. Lancet 1995;346:1494.
35. 35. Koiwai O, Nishikawa M, Hasada K, Aono S, Adachi Y, Mamiya N, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995;4:1183-6.
36. 36. Debinski HS, Lee CS, Dhillon AP, Mackenzie P, Rhode J, Desmond PV. UDP-glucuronosyltransferase in Gilbert's syndrome. Pathology 1996;28:238-41.
37. 37. Robertson KJ, Clarke D, Sutherland L, Wooster R, Coughtire MWH, Burchell B. Investigation of the molecular basis of the genetic deficiency of UDP-glucuronosyltransferase in Crigler-Najjar syndrome. J Inherit Metab Dis 1991;14:563-79.
38. 38. Black M, Billing BH, Heirwegh KPM. Determination of bilirubin UDP-glucuronyltransferase activity in needle-biopsy specimens of human liver. Clin Chim Acta 1970; 29:27-35.
39. 39. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UGT cDNAs with expression in COS-1 cells. J Biol Chem 1991;266:1043-7.
40. 40. Takahashi T, Fujiwara Y, Miyazaki M, Kurata T, Oguri T, Yokozaki M, et al. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin (SN-38) resistance [abstract]. Proc Am Soc Clin Oncol 1998;17:185A.
41. 41. Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997;57:2979-85.
42. 42. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997;8:1049-51.
43. 43. Saka H, Ando Y, Sugiura S, Asai G, Shimokata K, Chida M, et al. UGT1A1*28 pleomorphism may affect glucuronidation of SN-38 in CPT-11 chemotherapy [abstract]. Proc Am Soc Clin Oncol 1998;17:195A.